Loading patent…
AssigneeMerus N.V.
InventorsJeroen Jilles LAMMERTS VAN BUEREN, Mark THROSBY
Estimating the term…
The present disclosure relates to the field of therapeutic antibodies for the treatment of a subject with cancer. More in particular, it relates to treating cancer using an antibody or functional part, derivative and/or analogue thereof that comprises a variable domain that binds an extracellular part of EGFR in a combination treatment that further comprises administering a fluoropyrimidine, a platinum-based chemotherapeutic agent, a BCL-2 inhibitor or SN-38. The cancers can be head and neck cancer, gastric cancer, esophageal cancer, gastro-esophageal-junction cancer, non-small cell lung cancer or colorectal cancer. The disclosure also relates to pharmaceutical formulations, kit-of-parts and dosage regimes.
An antibody or functional part, derivative and/or analogue thereof that comprises a variable domain that binds an extracellular part of EGFR, for use in the treatment of a cancer in a subject, wherein the treatment further comprises administering a fluoropyrimidine, a platinum-based chemotherapeutic agent, a BCL-2 inhibitor, or SN-38.
A method of treating cancer in a subject, the method comprising administering an effective amount of an antibody or functional part, derivative and/or analogue thereof that comprises a variable domain that binds an extracellular part of EGFR, and a fluoropyrimidine, a platinum-based chemotherapeutic agent, a BCL-2 inhibitor, or SN-38, to the subject.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the cancer is a head and neck cancer, gastric, esophageal, gastro-esophageal-junction cancer, non-small cell lung cancer or colorectal cancer.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the cancer is a colorectal cancer.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the fluoropyrimidine is fluorouracil.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the antibody is ADCC enhanced.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the antibody is afucosylated.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the antibody is a multispecific antibody.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the antibody is a bispecific antibody.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the variable domain that binds an extracellular part of EGFR is a heavy chain variable region that comprises:
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the antibody comprises a second variable domain that does not bind EGFR.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the antibody comprises a second variable domain that binds LGR5.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the variable domain that binds LGR5 binds an epitope that is located within amino acid residues 21-118 of the human LGR5 sequence depicted in FIG. 1.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the variable domain that binds LGR5 is a heavy chain variable region that comprises:
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the antibody is petosemtamab.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the subject is a mammal, in particular a human.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein said treatment comprises providing 1500 mg of the antibody or functional part, derivative and/or analogue thereof to the subject.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the subject to be treated has not received prior anti-cancer therapy.
The antibody or functional part, derivative and/or analogue thereof, or the method of any one of the preceding claims, wherein the antibody or functional part, derivative and/or analogue thereof and the fluoropyrimidine, the platinum-based chemotherapeutic agent, the BCL-2 inhibitor, or SN-38 are administered to the subject simultaneously, separately, or sequentially.
The method of treating cancer in a subject of any one of the preceding claims, wherein the method comprises administering an effective amount of the antibody or functional part, derivative and/or analogue thereof, and an effective amount of the fluoropyrimidine, platinum-based chemotherapeutic agent, BCL-2 inhibitor, or SN-38, to the subject.
A pharmaceutical composition comprising an antibody or functional part, derivative and/or analogue thereof as defined in any one of the preceding claims and a fluoropyrimidine, a platinum-based chemotherapeutic agent, a BCL-2 inhibitor, or SN-38.
A kit of parts comprising
A combination of an antibody or functional part, derivative and/or analogue thereof as defined in any one of the preceding claims, and a fluoropyrimidine, platinum-based chemotherapeutic agent, BCL-2 inhibitor, or SN-38 as defined in any one of the preceding claims for use in the treatment of cancer in a subject in need thereof.
A combination of
A combination of
The use of an antibody or functional part, derivative and/or analogue thereof as defined in any one of the preceding claims and a fluoropyrimidine, a platinum-based chemotherapeutic agent, a BCL-2 inhibitor, or SN-38, in the manufacture of one or more medicaments, for the treatment of a cancer in a subject, wherein treatment comprises administering the antibody or functional part, derivative and/or analogue thereof and the fluoropyrimidine, the platinum-based chemotherapeutic agent, the BCL-2 inhibitor, or SN-38, simultaneously, separately, or sequentially.
Dependencies are inferred from the claim text.